A Comparative Study of the Impact of Two Bioactive Collagen Peptides on Skin Properties and Aging Hallmarks

This translational study compared the efficacy and onset of action of avvera™ oral collagen peptides versus an active control in improving key skin parameters. For in vitro experiments, normal human dermal fibroblasts (NHDF) were exposed to avvera™ or the active control and secreted pro-collagen I was quantified by ELISA. For in vivo assays, a clinical study conducted on 67 healthy women assessed hydration (Corneometer), barrier function/TEWL (Tewameter), and crow’s-feet wrinkle area and length (standardized 3D imaging) at baseline, day 28, and day 56. In vitro, NHDF exposed for 72 h to the corresponding peptide preparations showed similar increased pro-collagen I secretion, but a larger increase was elicited by avvera™, indicating a stronger pro-collagen-stimulating effect. The in vivo assays showed that both products improved hydration (≈ +29-43%) and reduced TEWL by day 56 (≈ −8-9%). In addition, both products reduced wrinkle area and length, but avvera™ produced significantly greater reductions at day 28 than the active control, conferring an early advantage. These findings link fibroblast activity with short-term clinical improvements, support the biological benefits of oral collagen peptides, and show that avvera™ has a dual action (enhancing skin hydration and barrier function) for greater early and faster visible skin benefits.